Solanezumab, or sola, binds the amyloid-βpeptides that aggregate and form plaques in the brain that are an early pathological feature of Alzheimer's disease. Sola binds the central epitope of monomeric amyloid-β, KLVFFAD, (PDB ID 4XXD) with picomolar affinity. This epitope is known as the nucleation site for Aβ oligomerization, and it is these oligomers of Aβ that are thought to be toxic to neurons.
2012 results of the EXPEDITION 1 & 2 phase 3 clinical trials were only mildly encouraging. but were said to be the "first evidence that targeting the amyloid cascade can slow the progression of disease.”
^Watt, Andrew D.; Crespi, Gabriela A. N.; Down, Russell A.; Ascher, David B.; Gunn, Adam; Perez, Keyla A.; McLean, Catriona A.; Villemagne, Victor L.; Parker, Michael W.; Barnham, Kevin J.; Miles, Luke A. (2014). "Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?". Acta Neuropathologica127 (6): 803–10. doi:10.1007/s00401-014-1290-2. PMID24803227.